SUNNYVALE, Calif., Oct. 27 /PRNewswire-FirstCall/ -- Cepheid (Nasdaq: CPHD) today noted an announcement from Birmingham Children's Hospital highlighting results using Cepheid's Xpert(TM) MRSA test, which runs on the GeneXpert(R) System, to implement a screening program for all patients being admitted to its Intensive Care Unit (ICU).
The Birmingham Children's Hospital announcement, released yesterday, stated that "obtaining an accurate and rapid result for MRSA is absolutely key at the emergency admission point in hospitals. For example, if a patient is critically ill and needs to be admitted to the ICU without delay, clinicians simply cannot afford to wait two to three days for a culture result to see whether the patient has MRSA."
"It made sense to start the screening with ICU patients as they are the most susceptible to contracting the MRSA infection due to the bacteria most commonly gaining access to the body through open wounds, injections, catheters and IV sites," said Dr. Jim Gray, Consultant Microbiologist at Birmingham Children's Hospital. "It is vital to prevent MRSA from entering the ICU as it is extremely serious and potentially fatal for children who are already critically ill."
According to the announcement, Cepheid's Xpert(TM) MRSA test has proven to be 100 percent accurate, allowing doctors at the hospital to identify MRSA carriers in under an hour. To validate the 100 percent accuracy rate of the on-demand results obtained using Xpert MRSA, all results so far have been verified with a traditional culture-based test, which takes up to three days for results. The hospital has already identified cases of MRSA that they would normally not have discovered prior to patient admission.
"This is another excellent example demonstrating the growing recognition of rapid molecular-based testing as the basis for best practice surveillance programs," said Rob Koska, Cepheid's Senior Vice President of Worldwide Commercial Operations. "As the leader in Healthcare Associated Infection (HAI) testing, Cepheid is committed to helping institutions worldwide implement the most effective programs that deliver proven results."
About the GeneXpert(R) System Molecular Diagnostic Platform
The GeneXpert(R) System is a closed, self-contained, fully-integrated and automated platform that represents a paradigm shift in the automation of molecular analysis, producing accurate results in a timely manner with minimal risk of contamination. The GeneXpert System is the only system to combine on-board sample preparation with real-time PCR (polymerase chain reaction) amplification and detection functions for fully integrated and automated nucleic acid analysis. The system is designed to purify, concentrate, detect and identify targeted nucleic acid sequences thereby delivering answers directly from unprocessed samples. Modular in design, the GeneXpert System has a variety of configurations to meet the broad range of testing demands of any clinical environment.
Based in Sunnyvale, Calif., Cepheid (Nasdaq: CPHD) is an on-demand molecular diagnostics company that develops, manufactures, and markets fully-integrated systems for genetic analysis in the clinical, industrial and biothreat markets. The company's systems enable rapid, sophisticated genetic testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. The company's easy-to-use systems integrate a number of complicated and time-intensive steps, including sample preparation, DNA amplification and detection, which enable the analysis of complex biological samples in its proprietary test cartridges. Through its strong molecular biology capabilities, the company is focusing on those applications where rapid molecular testing is particularly important, such as identifying infectious disease and cancer in the clinical market; food, agricultural, and environmental testing in the industrial market; and identifying bio-terrorism agents in the biothreat market. See http://www.cepheid.com for more information.
This press release contains forward-looking statements that are not purely historical regarding Cepheid's or its management's intentions, beliefs, expectations and strategies for the future, including those relating to product performance and future market growth. Because such statements deal with future events, they are subject to various risks and uncertainties, and actual results could differ materially from the company's current expectations. Factors that could cause actual results to differ materially include risks and uncertainties such as those relating to: unforeseen manufacturing problems; regulatory developments and changing practices; the failure of products to perform as expected, whether due to manufacturing errors, defects or otherwise; and underlying market conditions worldwide. Readers should also refer to the section entitled "Risk Factors" in Cepheid's Annual Report on Form 10-K for 2007 and in its most recent quarterly report on Form 10-Q, each filed with the Securities and Exchange Commission.
All forward-looking statements and reasons why results might differ
included in this release are made as of the date of this press release,
based on information currently available to Cepheid, and Cepheid assumes no
obligation to update any such forward-looking statement or reasons why
results might differ.
For Media Inquiries:
Cepheid Corporate Communications
For Cepheid Investor Inquiries:
Cepheid Investor Relations
Copyright©2008 PR Newswire.
All rights reserved